标题
Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2
作者
关键词
-
出版物
Nature Communications
Volume 12, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-03-09
DOI
10.1038/s41467-021-21825-w
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
- (2020) Shuai Xia et al. CELL RESEARCH
- Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study
- (2020) N. Lian et al. CLINICAL MICROBIOLOGY AND INFECTION
- Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
- (2020) Zhen Zhu et al. JOURNAL OF INFECTION
- A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
- (2020) David E. Gordon et al. NATURE
- SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes
- (2020) Waradon Sungnak et al. NATURE MEDICINE
- Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
- (2020) Shutoku Matsuyama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review
- (2020) Anwar M. Hashem et al. Travel Medicine and Infectious Disease
- The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
- (2020) Xi Wang et al. Cell Discovery
- Variant analysis of SARS-CoV-2 genomes
- (2020) Takahiko Koyama et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Disappearance of antibodies to SARS-CoV-2 in a -COVID-19 patient after recovery
- (2020) Anding Liu et al. CLINICAL MICROBIOLOGY AND INFECTION
- Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2
- (2020) Markus Hoffmann et al. NATURE
- Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
- (2020) Laura Riva et al. NATURE
- Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
- (2020) Pauline Maisonnasse et al. NATURE
- A perspective on potential antibody-dependent enhancement of SARS-CoV-2
- (2020) Ann M. Arvin et al. NATURE
- Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
- (2020) Quan-Xin Long et al. NATURE MEDICINE
- Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19
- (2020) F. Javier Ibarrondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Longer Duration of SARS-CoV-2 Infection in a Case of Mild COVID-19 With Weak Production of the Specific IgM and IgG Antibodies
- (2020) Xuemin Guo et al. Frontiers in Immunology
- SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment
- (2020) Mathieu E. Rebeaud et al. Frontiers in Medicine
- Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
- (2020) Mayla Gabriela Silva Borba et al. JAMA Network Open
- Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing
- (2020) Kelvin Kai-Wang To et al. CLINICAL INFECTIOUS DISEASES
- A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2
- (2020) Hanjun Zhao et al. Nature Communications
- Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
- (2020) Wen Shi Lee et al. Nature Microbiology
- Arbidol and other Low Molecular Weight Drugs That Inhibit Lassa and Ebola Viruses
- (2019) C. E. Hulseberg et al. JOURNAL OF VIROLOGY
- Dual-functional peptide with defective interfering genes effectively protects mice against avian and seasonal influenza
- (2018) Hanjun Zhao et al. Nature Communications
- Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol
- (2016) Rameshwar U. Kadam et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Novel residues in the PA protein of avian influenza H7N7 virus affect virulence in mammalian hosts
- (2016) Hanjun Zhao et al. VIROLOGY
- A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses
- (2016) Hanjun Zhao et al. Scientific Reports
- Structure, Function, and Evolution of Coronavirus Spike Proteins
- (2016) Fang Li Annual Review of Virology
- Protease inhibitors targeting coronavirus and filovirus entry
- (2015) Yanchen Zhou et al. ANTIVIRAL RESEARCH
- Pharmacokinetics, Metabolism, and Excretion of the Antiviral Drug Arbidol in Humans
- (2013) Pan Deng et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics of single and multiple oral doses of arbidol in healthy Chinese volunteers
- (2013) Yaxin Sun et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Recombinant mouse beta-defensin 2 inhibits infection by influenza A virus by blocking its entry
- (2010) Tianxiang Gong et al. ARCHIVES OF VIROLOGY
- Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus
- (2008) B.-J. Zheng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More